Formulation, Evaluation and Comparison of Mesalamine compression coated tablets by using Natural and Semi synthetic polymers
Abstract
The main objective of this research paper is to formulate, evaluate and compare compression-coated tablets of Mesalamine using natural and synthetic polymer. The natural polymers used were pectin and Xanthan gum and the synthetic polymer used was HPMC E50 LV. Initially tablets were prepared by direct compression method using different polymers and both pre-compression and post-compression evaluation was conducted. Using the same polymers compression coated tablets of mesalamine were prepared by compression coating method using Cellulose acetate phthalate as the enteric polymer. These tablets were also subjected to pre-compression and post-compression evaluation and all the values obtained were in acceptable limits. Dissolution studies were conducted in different media having pH 1.2, 6.8 and 7.4. The dissolution results showed the drug release of uncoated tablet of HPMC E50 LV was 108.42% at 480 minutes, Pectin was 100.53% at 300 minutes and Xanthan gum was 108.73% at 90 minutes. The drug release of coated tablets of HPMC E50 LV was 100.42% at 680 minutes, Pectin was 102.31% at 580 minutes and Xanthan gum was 100.42% at 300 minutes. Hence the study showed that the compression coated tablets of mesalamine using HPMC E50 LV showed delayed release of the drug in 680 minutes.
Keywords: Mesalamine, Colon targeting drug delivery system, Compression coating method, Delayed release, Cellulose acetate phthalate.
Keywords:
Mesalamine, Colon targeting drug delivery system, Compression coating method, Delayed release, Cellulose acetate phthalateDOI
https://doi.org/10.22270/jddt.v12i4-S.5606References
Banerjee A, Qi J, Gogoi R, Wong J, Mitragotri S. Role of nanoparticle size, shape and surface chemistry in oral drug delivery. Journal of Controlled Release. 2016; 176-185. https://doi.org/10.1016/j.jconrel.2016.07.051
Araújo F, Pedro J, Granja P L, Santosh A, Sarmento B. Functionalized materials for multistage platforms in the oral delivery of biopharmaceuticals. Progress in Materials Science. 2017; 89:306-344. https://doi.org/10.1016/j.pmatsci.2017.05.001
Hu Q, Luo Y. Recent advances of polysaccharide-based nanoparticles for oral insulin delivery. International Journal of Biological Macromolecules. 2018; 120(Pt A):775-782. https://doi.org/10.1016/j.ijbiomac.2018.08.152
Choi H J, Ebersbacher C F, Kim M, Kang S M, Montemagno C D. A mechanistic study on the destabilization of whole inactivated influenza virus vaccine in gastric environment. PLOS ONE. 2013; 8(6):456-462. https://doi.org/10.1371/journal.pone.0066316
Schenk M, Mueller C. The mucosal immune system at the gastrointestinal barrier. Best Practice & Research Clinical Gastroenterology. 2008; 22(3):391-409. https://doi.org/10.1016/j.bpg.2007.11.002
Ensign LM, Cone R Hanes. J. Oral drug delivery with polymeric nanoparticles. The gastrointestinal mucus barriers. Advanced Drug Delivery Reviews. 2012; 64 (6):557-570. https://doi.org/10.1016/j.addr.2011.12.009
Godge RK, Kendre PN, Giri MA, Syed MZ, Syed NL et al. Formulation and In-Vitro Evaluation of Fast Dissolving/Disintegrating tablets of Tizanidine Hydrochloride. Research Journal of Pharmaceutical Dosage Forms and Technology. 2009; 1(1):55-58. https://rjpdft.com/AbstractView.aspx?PID=2009-1-1-12
Leon Lachman, Herbert A. Lieberman. Granulation properties in “the theory and practice of industrial pharmacy”. Varghese publishing house; 1990. 3rd ed. 315-319.
Vaidya A, Jain A, Khare P, Agrawal RK, Jain SK. Metronidazole Loaded Pectin Microspheres for Colon Targeting. Wiley Inter Science (www.interscience.wiley.com). 2009; 98(11):4229 – 4236 https://doi.org/10.1002/jps.21742
M. Katsuma, Watanabe, Kawai, S. Takemura. Masuda, M. Fukui. Studies on lactulose formulations for colon-specific drug delivery. J- Stage. 2009; 69(1):34-39. https://doi.org/10.14843/jpstj.69.34
Seung H L, Jeong E K, Mi L C. Immunological pathogenesis of Inflammatory Bowel Disease. NIH. 2018; 16(1): 26–42 https://doi.org/10.5217/ir.2018.16.1.26
Katsuma M, Watanabe S, Takemura S et al. Scintigraphic evaluation of a novel colon-targeted delivery system (CODES™) in healthy volunteers. Journal of Pharmaceutical Sciences. 2004; 93(5):1287-1299. https://doi.org/10.1002/jps.20063
Kuhbacher T, Folsch UR. Practical guidelines for the treatment of inflammatory bowel disease. World Journal of Gastroenterology.2007; 13(8):1149-1155. 10.3748/wig. v13.i8.1149]
Philip AK, Philip B. Colon Targeted Drug Deliver Systems: A Review on Primary and Novel Approaches. Oman Medical Journal. 2010; 25: omj.2010.24
Chourasia MK, Jain SK. Polysaccharides for Colon targeted drug delivery. Tailor & Francis Online. 2004; 11(2):129-148. https://doi.org/10.1080/10717540490280778
Katsuma S, Watanabe H K, S. Takemura, K. Sako. Effects of absorption promoters on insulin absorption through colon-targeted delivery. International Journal of Pharmaceutics. 2006; 307 (2):156-162. https://doi.org/10.1016/j.ijpharm.2005.09.028
Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in-vitro/in-vivo evaluation. International Journal of Pharmaceutics. 2002; 235(1,2):1-15. https://doi.org/10.1016/S0378-5173(02)00004-2
Kedia P, Cohen RD. Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis. Therapeutics and Clinical Risk Management. 2007; 3(5):919-27.
Hu MY, Peppercorn MA. MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis. Expert Opinion on Pharmacotherapy. 2008; 9(6):1049-1058. https://doi.org/10.1517/14656566.9.6.1049
Cada D, Baker D, Levien T. Formulary drug reviews-mesalamine. Hospital Pharmacy. 2007; 4(3):160-170. https://doi.org/10.1038/ncpgasthep0696
Published
Abstract Display: 751 
PDF Downloads: 701 PDF Downloads: 50 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.